Investment Snapshot
Stock Price
Accumulate $5
Winning Scenario
Over $20
Base Case (PWV)
$35–45/share*
* Probability-adjusted value if OCCC hits Short Term Target
Short Term Target
$8-$10
Editors Note: The shares are oversold, continue trending in the plus $4 range, the wild swings down on the chart are likely shorts hunting stop losses. The Stock is a pressure cooker at these levels.
RISK: The stock is a box checker, low float, Cancer and well-funded, we also believe the short position is underreported. Easily over $20 if the upcoming scenario plays out.
Catalysts:
1B/2 Trial – Ovarian Clear Cell Cancer
Investors,
Preliminary results for (NASDAQ:LIXT) looks to be as promising as the decades of research have shown in the fight against Cancer.
The ongoing GSK study is expected to yield results in the upcoming quarter and Smart investors will take a position, and hold heading into this news.
“We think the stock is an easy double from here, as there isn’t much resistance under $5. So, the Goldilocks zone is $5 to $8 as we await upcoming results.”
The market cap is under $20M and the float is under 5M shares, which makes this stock a “fast moving stock” on news.
While LIXT, hit a high of around $5 after the initial news, and our alert at $1.26 the upcoming news could see a complete repricing of the stock overnight, as “Efficacy” is proven for these 2 specific types of tumors.
Most early-stage cancer compounds never receive financial backing from major pharmaceutical companies in fact, fewer than 5% move beyond simple drug-supply agreements but LB-100 has broken through that barrier. GSK is not only providing their flagship drug for combination trials, but also committed funding and resources, a rare move that underscores the exceptional promise they see in this therapy.
Big Pharma simply doesn’t make these kinds of investments unless expectations are high and the potential is significant. For investors, this represents a powerful vote of confidence that LB-100 could play a transformative role in enhancing frontline cancer treatments and driving meaningful commercial value.
LIXTE’s (NASDAQ:LIXT) last run was in July during the heat of the summer. The upcoming results are expected to be released when the market is at full power. Expectations couldn’t be higher and we could see the stock easily in the teens with positive results.
Especially if the trials
are good!
Positive results could easily trigger many more exciting catalysts here, as the biggest players in the cancer research and treatment in the world have tested LB-100 and could easily buy the whole company, even if the stock were at $10 giving them a $40 million market cap.
Keeping this in context the trials probably cost 6 million each.
LIXTE has cash in the bank and GSK paid for the ongoing trial, so there is nothing left but to wait for upcoming news of preliminary and ongoing results.
It’s been a great month for short sellers who have been doing well in August, but as rate cuts get closer, and vacation is over, look for over aggressive, and overleveraged positions to get squeezed. LIXT is hard to borrow, with 400% maintenance costs as I’m writing this.
As preliminary results and more studies come out, the media will be in full swing for Cancer news, and more media equals more investors, which will create a feeding frenzy surrounding this stock.
Go read the full report for more details, watch the video, and make sure you sign up to get additional alerts and news on LIXT.
You don’t want to miss it.
Invest Now
Do yourself a favor and sign up to receive breaking news Alerts so you don’t miss out on updates about LIXTE Biotechnology.
DISCLOSURE: 24/7 Market News Inc. (247), owns and operates 247marketnews.com is a third-party publisher and news release service provider which disseminates corporate news electronically through multiple online media platforms. 247 is NOT an affiliate with any of the companies mentioned in our reports. 247 is a news distribution service and is not registered with FINRA or any other professional licensing service. 247 is not an analyst, broker dealer or advisor, and holds no such licenses. 247 may NOT offer to buy, sell, or hold any security. 247 Venture Beats, and Breakfast bits and any other corporate profiles will NEVER be a solicitation or recommendation of any kind, of any security mentioned. The materials in all our releases are intended to be for informational purposes only and should never be considered research or due diligence on any company mentioned. All readers are encouraged to perform standard due diligence by reading the company’s filings at SEC.gov. Readers should consult their broker or licensed professional before investing in any company. All materials in this release are based on publicly available statements made by the companies. 247 is not liable for any investment decisions made by any readers or subscribers. Any investment could result in you losing all your money from investing in any stock. 247’s editor owns no shares of Lixtie Biotechnology Holdings Inc., LIXT and will not trade in the stock. Publisher has been paid for ongoing investor outreach, and news coverage by Microcap strategy on behalf of the company of up to twenty-five thousand dollars a week for the next three months. 24/7 will also be using financial marketing tools to engage with the investment community online. Editors are paid to put a best-case scenario profile out to the investing public. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements. Or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements. Or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements. Including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements. Including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements.
All information, opinions, analyses, technical analysis, trading price targets, and support and resistance interpretations presented in this publication represent the author’s personal views and are fully protected under the First Amendment of the United States Constitution. The content provided herein is intended solely as editorial opinion, general market commentary, or educational material, and should never be construed as financial or investment advice. This publication does not constitute a solicitation or recommendation to buy or sell securities, commodities, or any other financial instruments. Readers are strongly advised to conduct their own independent research or seek professional advice before making any investment decisions. For additional information regarding First Amendment protections for financial newsletters and commentary, please refer to Lowe v. SEC, 472 U.S. 181 (1985): https://supreme.justia.com/cases/federal/us/472/181/
Copyright © 2025 24/7 MarketNews